ESC 365 - Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

ESC2025 Premium Access

Impact of Nebivolol versus Carvedilol on long-term outcomes on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

Session: Pharmacotherapy in acute coronary syndromes (4)

Topic: ST-Elevation Myocardial Infarction (STEMI)

Speaker: Doctor M. Susanti (Jawa Timur, ID)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Melly Susanti

Ministry of Health Surabaya Central General Hospital, Jawa Timur (Indonesia)

0 follower

4 more presentations in this session

Aspirin does not reduce cardiovascular risk in smokers across coronary calcium scores after coronary computed tomography angiography

Speaker: Mr G. Winther (Aalborg, DK)

Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy presenting with ACS - a systematic review and meta-analysis

Speaker: Doctor B. Hakkeem (Kozhikode, IN)

Impact of beta-blocker nebivolol versus carvedilol prescription at discharge on long-term clinical outcomes in STEMI patients with reduced LVEF treated with drug-eluting stents

Speaker: Professor S. Park (Seoul, KR)

Safety and effectiveness of tegoprazan in patients treated with dual antiplatelet therapy after drug-eluting stent implantation for acute myocardial infarction.

Speaker: Doctor O. Lee (Yongin, KR)

Access the full session

Pharmacotherapy in acute coronary syndromes (4)

Speakers: Doctor M. Susanti, Mr G. Winther, Doctor B. Hakkeem, Professor S. Park, Doctor O. Lee

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources